Resources about TB
and TB Vaccine R&D
- Meeting Report: 6th Global Forum on TB Vaccines, 22 - 25 February 2022, published open access in Vaccine: X
- TB Vaccines Pipeline Report is an annual report from Treatment Action Group (TAG) that reviews progress in the clinical development of TB vaccines. The report is updated annually.
- Platforms in the TB Vaccine Pipeline provides an overview of the different platforms - or types of vaccines - in the TB vaccine pipeline
- Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis. This follow-up to the 2019 report by the Lancet Commission outlines roadblocks that have undermined progress towards ending TB over the past five years and provides recommendations, lessons that can be learned from teh global response to COVID-19, and how a new set of diagnostics, therapeutic, and preventive tools - including new vaccines - already available or in the pipeline promises the possibility of transformative progress.
- Global Tuberculosis Report, published by the WHO, provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease at global, regional and country levels. The report is updated annually.
- Global roadmap for research and development of tuberculosis vaccines, published by EDCTP and the Amsterdam Institute for Global Health and Development (AIGHD) in close collaboration with WHO, identifies priorities for the development and implementation of new TB vaccines with the aim to coordinate and accelerate global action.
- TB Vaccine Development: The Next Chapter Starts Now is a webinar organized by Treatment Action Group and intended for the community, civil society, advocates, and other interested stakeholders. The webinar provides an overview of the TB vaccine pipeline, scientific challenges in TB vaccine development, and advocacy opportunities
- WHO Preferred Product Characteristics for New Tuberculosis Vaccine presents WHO preferences for new tuberculosis vaccines, driven by the high medical need for contribution to the fight against TB, in alignment with the End TB strategy.
- TB Vaccine Development Pathway, developed by IAVI and TBVI, is an online tool that provides a structured development path and gating criteria for TB vaccine candidates. It includes considerations for target populations, vaccine platforms, and market, access and implementation, as well as guidance for planning and operating community engagement activities.
- Tuberculosis Vaccines for Adults and Adolescents: Progress, Prospect, and Perspectives is a webinar organized by the Global Vaccine and Immunization Research Forum (GVIRF) that brought together experts to discuss the status of TB vaccine development across the value chain, from articulation of the public health and economic need for new TB vaccines through the status and strategies for product development, to the considerations for approval, policy recommendation and use. Video in English | Video in Spanish | Video in French | Presentations
- Directory of TB Vaccine Clinical Trial Sites in Sub-Saharan Africa, provided by EDCTP, provides a comprehensive overview of trial sites and their capacity to conduct studies of TB vaccines in sub-Saharan Africa.
- BCG World Atlas is an interactive map that provides detailed information on current and past BCG vaccination policies and practices for over 180 countries.
Contact us if you have resources about TB and TB vaccines that you would like to share.
Resources for Advocacy, Policy, and Funding
- End TB Strategy from the World Health Organization’s Global TB Programme provides a 20-year strategy toward the goal of ending the TB epidemic, including research, development, and implementation of new tools.
- Global Plan to End TB 2023-2030, published by the Stop TB Partnership, is a costed plan and roadmap for a concerted response to tuberculosis (TB) aligned with the WHO End TB Strategy, including a strategic framework for TB vaccine R&D.
- Report on Tuberculosis Research Funding Trends, published annually by TAG, tracks how much public, private, philanthropic, and multilateral institutions spend on TB research and development (R&D) across six areas of research: basic science, diagnostics, drugs vaccines, operational research, and infrastructure/unspecified projects.
- An investment case for new TB vaccines summarizes the results of a full value proposition for new tuberculosis (TB) vaccines commissioned by WHO to provide early evidence for national and global decision-makers involved in TB vaccine development and implementation, who include stakeholders involved in vaccine research, financing, regulation and policy-making, manufacturing, introduction and procurement. A Q&A on how this work can be best used for TB vaccine advocacy is available here.
- Investment Toolbox to Advance TB Vaccine Development through Joint Action is a policy brief co-authored by the TB Vaccine Advocacy Roadmap (TB Vax ARM) that outlines recommendations for G20 members to act together to accelerate TB vaccine development. The proposed "investment toolbox' is adaptable to each country's economic and research capacities and disease burden.
- New TB vaccines needed to tackle AMR, published by TB Vax ARM, shares a collective call to decision-makers to prioritize TB vaccine R&D as a signature piece of global health and antimicrobial resistance (AMR) agendas. The brief, from the TB Vax ARM, draws on the latest research in health and economic modelling to demonstrate how new TB vaccines could significantly help control drug-resistant TB, in a cost-effective and affordable way.
- Accountability to End Tuberculosis: A Global Responsibility, published by RESULTS UK, looks ahead to the UNHLM in September 2023 and makes the case for accountability within the global TB response, highlighting the lack of progress against the 2018 global commitments and the role of accountability within these commitments.
- The Urgent Need for New TB Vaccines, published by TB Vax ARM, provides information and talking points about the importance of TB vaccines to meeting global targets to end TB and the need to invest in TB vaccine research and development.
- Words Matter, published by Stop TB Partnership, is a communications tool for partners, stakeholders, and anyone affected or working in TB. The guide is a key instrument to encourage positive change, sensitize, promote appropriate language, end the stigmatization, and empower people affected by TB.
- Modeling in TB vaccine development provides an overview of mathematical modeling for TB vaccines, like public health impact and cost-effective modeling, and how modeling can be used to support TB vaccine advocacy efforts.
- A Deadly Divide: TB Commitments vs TB Realities. Developed by the Stop TB Partnership Communities, Developing Country NGO, and Developed Country NGO Delegations to the Board with input from more than 1,000 civil society and affected community partners from 92 countries, this report analyzes progress against a series of commitments made by world leaders at the United Nations High-Level Meeting on TB (UNHLM) in 2018 and lays out priorities and six calls to action that are required to end the TB epidemic.
- Video - Phumeza Tisile talk about her challenges in facing extensively drug-resistant TB, her vision of a TB free world, and how we can achieve it with new TB vaccines.
- Member States must commit to invest in TB vaccine R&D, published by TB Vax ARM, is a one page document with information on the public health rationale for why Member States must commit to substantially increasing adequate, predictable, and sustainable financing for TB vaccine research at the UN High-Level Meeting on TB.
- Recording: Prioritizing TB R&D at the UNLHM on TB and Beyond. Representatives from Global Health Advocates, RESULTS UK, RESULTS Canada, the the TB Vax ARM to present on recent TB R&D advocacy activities ahead of the HLM.
- New Fair Share Targets for TB Research: 0.1% -> 0.15%. In 2017, Treatment Action Group (TAG) and partners introduced the 'fair share' funding targets for TB research calling for each country to spend at least 0.1% of its overall research and development (R&D) expenditures on TB R&D in order to meet global TB research funding goals. In August, TAG released an updated Information note providing details on the new 0.15% fair share funding targets for TB research, and the methodology and sources of data behind them.
- Ready Next Time is a report by Campaigns in Global Health that maps the intersection between efforts to strengthen pandemic prevention, preparedness and response (PPPR) systems and efforts to end TB. It sets out how policymakers and funders can deliver impact across both agendas, saving lives today and tomorrow and helping to make the case for sustained investment in public health.
Contact us if you have resources related to advocacy, policy, and funding for TB vaccine R&D that you would like to share.
Resources for Community Engagement
- Good Participatory Practice Guidelines for TB Vaccine Research, published by Aeras, is a user- friendly framework that defines specific standards and key elements needed for creating effective partnerships with stakeholders throughout the entire research process.
- An Activist's Protocol Review Toolkit, developed by TAG in consultation with members of the Global TB Community Advisory Board and the Community Research Advisory Group, is designed to facilitate community participation in the development and review of clinical trials protocols.
- Frequently Asked Questions on TB Vaccine Research, published by IAVI, is a fact sheet that provides information and answers to commonly asked questions about TB vaccine research.
- Myths and Facts about TB Vaccine Research, by IAVI, is a fact sheet that responds to some common misconceptions about vaccine research.
- Tuberculosis Vaccines and Clinical Trials, published by IAVI, provides information about TB, vaccines, and clinical trials in an illustrative and easy to understand booklet.
- Being Part of Tuberculosis Vaccine Clinical Trials is a speaking book published by Books of Hope in collaboration with Aeras, that provides potential clinical trial participants with information about tuberculosis and what is involved in participating in a clinical trial. The information is in both English and Afrikaans.
Contact us if you have community engagement resources and materials that you would like to share.
Recent Scientific Publications
- What is next for BCG revaccination to prevent tuberculosis? White RG, Fiore-Gartland AJ, Hanekom WA, Vekemans J, Garcia-Basteiro AL, Churchyard G, Rangaka MX, Frick M, Behr MA, Hill PC, Mave V. Lancet Respir Med. 2024 Mar. doi: 10.1016/S2213-2600(24)00009-2. Epub 2024 Jan 22.
- BCG infection dose guides dendritic cell migration and T cell priming in the draining lymph node. Krmeská V, Shen L, Nylén S, Wowk PF, Rothfuchs AG. Scand J Immunol. 2024 Mar. doi: 10.1111/sji.13342. Epub 2023 Nov 21.
- Nanotechnology of inhalable vaccines for enhancing mucosal immunity. Qin L, Sun Y, Gao N, Ling G, Zhang P. Drug Deliv Transl Res. 2024 Mar. doi: 10.1007/s13346-023-01431-7. Epub 2023 Sep 25.
- Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control. Gong W, Du J. Lancet Infect Dis. 2024 Mar. doi: 10.1016/S1473-3099(23)00514-5. Epub 2023 Nov 25.
- Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial. Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, Oduru G, Nassuuna J, Kabagenyi J, Morrison H, Scott H, Doherty RP, Marshall JL, Puig IC, Cose S, Kaleebu P, Webb EL, Satti I, McShane H, Elliott AM; TB042 Study Team. Lancet Infect Dis. 2024 Mar. doi: 10.1016/S1473-3099(23)00501-7. Epub 2023 Nov 25.
- OMIP-101: 27-color flow cytometry panel for immunophenotyping of major leukocyte populations in fixed whole blood. Imbratta C, Reid TD, Toefy A, Scriba TJ, Nemes E. Cytometry A. 2024 Mar. doi: 10.1002/cyto.a.24827. Epub 2024 Feb 11.
- Construction and expression of Mycobacterium tuberculosis fusion protein SHR3 and its immunogenicity analysis in combination with various adjuvants. Zhang Z, Xu L, Wang X, Kong L, Shi Z, Zhong Q, Xu Y, Wang J. Tuberculosis (Edinb). 2024 Mar. doi: 10.1016/j.tube.2024.102480. Epub 2024 Jan 23.
- Phospholipase C epsilon-1 (PLCƐ1) mediates macrophage activation and protection against tuberculosis. Gupta A, Thirunavukkarasu S, Rangel-Moreno J, et al. Infect Immun. Published online March 7, 2024. doi:10.1128/iai.00495-23
- Multiple genetic loci influence vaccine-induced protection against Mycobacterium tuberculosis in genetically diverse mice. Kurtz SL, Baker RE, Boehm FJ, Lehman CC, Mittereder LR, Khan H, Rossi AP, Gatti DM, Beamer G, Sassetti CM, Elkins KL. PLoS Pathog. 2024 Mar 7. doi: 10.1371/journal.ppat.1012069. Epub ahead of print.
- BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in mice. Kwon KW, Choi HG, Kim KS, Park SA, Kim HJ, Shin SJ. NPJ Vaccines. Published 2024 Mar 8. doi:10.1038/s41541-024-00847-7
- Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development. Chugh S, Bahal RK, Dhiman R, Singh R. NPJ Vaccines. 2024 Mar 9. doi: 10.1038/s41541-024-00834-y.
- Exploring the immunogenicity of Rv2201-519: A T-cell epitope-based antigen derived from Mycobacterium tuberculosis AsnB with implications for tuberculosis infection detection and vaccine development. Luan X, Fan X, Li G, Li M, Li N, Yan Y, Zhao X, Liu H, Wan K. Int Immunopharmacol. 2024 Mar 10. doi: 10.1016/j.intimp.2024.111542. Epub 2024 Feb 10.
- Analyzing human CD4+ T cells activated in response to macrophages infected with Mycobacterium tuberculosis. Gail DP, Suzart VG, Carpenter SM. STAR Protoc. 2024 Mar 15. doi: 10.1016/j.xpro.2024.102939. Epub 2024 Mar 6.
- Synthesis of an Immunologically Active Heptamannoside of Mycobacterium tuberculosis by the [Au]/[Ag]-Catalyzed Activation of Ethynylcyclohexyl Glycosyl Carbonate Donor. Shinde GP, Sutar Y, Kasdekar N, Joshi P, Rasool O, Ignatowicz L, Hamasur B, Hotha S. Org Lett. 2024 Mar 15. doi: 10.1021/acs.orglett.4c00175.
- Optimizing antigen selection for the development of tuberculosis vaccines. Yang Y, Chen YZ, Xia T. Cell Insight. 2024 Mar 16. doi: 10.1016/j.cellin.2024.100163.
- Immunogenicity and protective efficacy of RipA, a peptidoglycan hydrolase, against Mycobacterium tuberculosis Beijing outbreak strains. Kwon KW, Choi HG, Choi HH, Choi E, Kim H, Kim HJ, Shin SJ. Vaccine. 2024 Mar 19. doi: 10.1016/j.vaccine.2024.02.039. Epub 2024 Feb 16.
- Impact of BCG Vaccination Disruptions During the COVID-19 Pandemic on Tuberculosis Incidence in Infants: A Nationwide Study in Brazil. Procianoy GS, Cotrim MW, Cia LO, Behar PRP. J Pediatric Infect Dis Soc. 2024 Mar 19. doi: 10.1093/jpids/piae013.
- Discovering peptides and computational investigations of a multiepitope vaccine target Mycobacterium tuberculosis. Nguyen TL, Kim H. Synth Syst Biotechnol. 2024 Mar 21. doi: 10.1016/j.synbio.2024.03.010.
- Pivotal tuberculosis vaccine trial begins. Burki T. Lancet. 2024 Mar 23. doi:10.1016/S0140-6736(24)00579-8
- Rapamycin improves the long-term T-cell memory and protective efficacy of tuberculosis subunit vaccine. Niu H, Bai C, Zhu B, Zhang Y. Microb Pathog. 2024 Mar 26. doi: 10.1016/j.micpath.2024.106631. Epub ahead of print.
- Application of CRISPR-cas-based technology for the identification of tuberculosis, drug discovery and vaccine development. Shi L, Gu R, Long J, Duan G, Yang H. Mol Biol Rep. 2024 Mar 29. doi: 10.1007/s11033-024-09424-6.
Contact us with recent publications (within last 30 days) sharing new data, approaches, and information on TB vaccine R&D